ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. More Details
High growth potential and fair value.
Share Price & News
How has ERYTECH Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ERYP is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ERYP's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ERYP underperformed the French Biotechs industry which returned 35.7% over the past year.
Return vs Market: ERYP underperformed the French Market which returned 48.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ERYTECH Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAnalysts Expect Breakeven For ERYTECH Pharma S.A. (EPA:ERYP) Before Long
1 month ago | Simply Wall StIs ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?
3 months ago | Simply Wall StERYTECH Pharma's (EPA:ERYP) Stock Price Has Reduced 60% In The Past Five Years
Is ERYTECH Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ERYP (€5.38) is trading below our estimate of fair value (€8.37)
Significantly Below Fair Value: ERYP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ERYP is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: ERYP is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ERYP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ERYP is good value based on its PB Ratio (4.1x) compared to the FR Biotechs industry average (4.3x).
How is ERYTECH Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ERYP is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.4%).
Earnings vs Market: ERYP is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ERYP's is expected to become profitable in the next 3 years.
Revenue vs Market: ERYP's revenue (70.5% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: ERYP's revenue (70.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ERYP's Return on Equity is forecast to be high in 3 years time
How has ERYTECH Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ERYP is currently unprofitable.
Growing Profit Margin: ERYP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ERYP is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare ERYP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ERYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: ERYP has a negative Return on Equity (-254.93%), as it is currently unprofitable.
How is ERYTECH Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ERYP's short term assets (€49.6M) exceed its short term liabilities (€29.3M).
Long Term Liabilities: ERYP's short term assets (€49.6M) exceed its long term liabilities (€24.5M).
Debt to Equity History and Analysis
Debt Level: ERYP's debt to equity ratio (62.7%) is considered high.
Reducing Debt: ERYP's debt to equity ratio has increased from 1.2% to 62.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ERYP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ERYP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.3% each year
What is ERYTECH Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ERYP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ERYP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ERYP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ERYP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ERYP's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gil Beyen (58 yo)
Mr. Gil Beyen, BVBA has been the Chief Executive Officer of ERYTECH Pharma S.A. since May 2013. For more than ten years, Mr. Beyen has been a Management Consultant at Arthur D. Little in Brussels and serve...
CEO Compensation Analysis
Compensation vs Market: Gil's total compensation ($USD1.16M) is above average for companies of similar size in the French market ($USD470.41K).
Compensation vs Earnings: Gil's compensation has increased whilst the company is unprofitable.
Experienced Management: ERYP's management team is considered experienced (4.9 years average tenure).
Experienced Board: ERYP's board of directors are considered experienced (8.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.7%.
ERYTECH Pharma S.A.'s company bio, employee growth, exchange listings and data sources
- Name: ERYTECH Pharma S.A.
- Ticker: ERYP
- Exchange: ENXTPA
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €138.707m
- Shares outstanding: 25.78m
- Website: https://www.erytech.com
Number of Employees
- ERYTECH Pharma S.A.
- 60 Avenue Rockefeller
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is ery...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/15 19:16|
|End of Day Share Price||2021/05/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.